Koyfin Home > Directory > Health Care > Lantheus Holdings

Lantheus Holdings Price Chart LNTH

Historical daily share price chart and data for Lantheus Holdings since 2015 adjusted for splits and dividends. The latest closing price for Lantheus Holdings as of September 18, 2020 is $12.92.
  • In 2020 the stock opened at $20.67 and closed at $12.92 for a loss of -60% YTD.
  • In 2019 the stock opened at $15.40 and closed at $20.51 for a gain of 25%.
  • In 2018 the stock opened at $20.60 and closed at $15.65 for a loss of -32%.
  • In 2017 the stock opened at $8.65 and closed at $20.45 for a gain of 58%.
View Chart On Koyfin

Lantheus Holdings Summary

Stock Symbol: LNTH

Lantheus Holdings Company Info

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting research and development on PD-L1 immuno-oncology treatments. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
209.45 %
30D Volatility
Hedge Fund Held
5.18 %

Last 10 Days of LNTH Prices